

PARTNERSHIP FOR
clean competition

ANNUAL REPORT

2021
EDITION

1 Olympic Plaza
Colorado Springs, Co. 80909

  @PCCAntiDoping
cleancompetition.org

ABOUT THE PCC

Doping is a global problem.
We fund solutions.

THE PARTNERSHIP FOR CLEAN
COMPETITION IS A NONPROFIT, 501(C)(3)
ORGANIZATION WORKING TO PROTECT
THE INTEGRITY OF SPORT AND PUBLIC
HEALTH BY ENGAGING AND
SUPPORTING THE WORLD'S TOP
SCIENTISTS AND INNOVATORS IN HIGH-
QUALITY ANTI-DOPING RESEARCH AND
DEVELOPMENT.

**PROTECTING ATHLETES
THROUGH A COMMITMENT
TO FUNDING HIGH QUALITY
ANTI-DOPING SCIENCE.**

PCC Founding Members





TABLE OF CONTENTS

4 LETTER FROM EXECUTIVE DIRECTOR

6 BOARD OF GOVERNORS

7 STAFF AND OFFICERS

8 SCIENTIFIC ADVISORY BOARD

12 A YEAR IN REVIEW

18 FINANCIAL OVERVIEW

A Letter from Executive Director Ryan Murphy



PCC Supporters,

Since the first grant funded back in 2008, the Partnership for Clean Competition (PCC) has been front and center in the anti-doping field - a field that was challenged in many ways throughout the pandemic. Over the course of the last few years, the PCC has been able to adapt and adjust to better support our key stakeholders in the fight for clean sport.

2021 saw some unique challenges for the organization. With the departure of the former Executive Director in April 2021, the PCC had the obligation to ensure that the work that we do did not slow down during the transition. When I started at the PCC in November 2021, I saw the strong position that the organization was in, due to the support of the PCC Board of Governors, the PCC Scientific Advisory Board, and the Director of Communications.

The core of the PCC's mission remains funding exceptional anti-doping research and supporting the laboratories and scientists who work in anti-doping science. The PCC funded over \$2.5 million in total research projects in 2021. The organization saw an increase in applications globally throughout the year. The PCC received applications from 23 countries across six continents that resulted in direct funding to projects in ten countries across four continents.

The PCC was able to expand its impact in the anti-doping space by coordinating a Virtual Poster Session that included 58 total posters presented. Over 75 live attendees joined the PCC's leadership team in viewing the Poster Session, while more than 500 views were recorded on the PCC's YouTube channel. To build on the success of the Virtual Poster Session, the PCC coordinated an Olympic and Paralympic Webinar Series which included over 125 live attendees and over 400 total playback views of the series.

Another milestone for the PCC came in the form of our digital impact across all platforms: website users, Instagram followers, Facebook followers, and Twitter followers. The Anti-Doping Podcast also saw its listeners grow 10.4% for the year, and 24 podcast episodes published.

As we reflect on another successful and productive year, we look forward to what is around the corner for the PCC. We would like to thank our all of our dedicated stakeholders for their support, especially our Founding Members and Contributors, dedicated Board Members, dedicated Scientific Advisory Board, the research scientists, and the laboratories around the world who continue to do all that they can to keep sport clean.

Sincerely,

Ryan M. Murphy
Executive Director

LEADERSHIP




BOARD OF GOVERNORS



Board Chair

Jon Coyles
*Major League
Baseball*

Jon Coyles serves as Vice President of Drug, Health and Safety Programs at Major League Baseball. In his current role, Coyles is responsible for overseeing all aspects of Major League Baseball's various drug prevention and treatment programs, including the management of the programs' scientific experts, medical consultants, specimen collection agents, and testing laboratories. Coyles also plays a key role in collective bargaining negotiations with the Major League Baseball Players Association, including the annual review and update of the Joint Drug Program. Before joining MLB, Coyles earned his Juris Doctor degree from the University at Buffalo School of Law and did his undergraduate work at the University of Rochester, where he graduated with degrees in Political Science and Psychology.



Kevin Manara
*National Football
League*

Kevin Manara served as Vice President of Labor Relations & Policy for the NFL. His responsibilities included the administration of the League's collective bargaining agreement with its players, as well as enforcement of the League's policies on performance-enhancing substances, personal conduct and substances of abuse. Kevin represented NFL clubs in grievances filed by players under the CBA, prosecuted appeals of discipline imposed under League policies and advised clubs on a variety of contractual, disciplinary and other labor-related matters. Prior to joining the NFL, Kevin was an associate in the Labor & Employment department at Proskauer. Kevin graduated from Johns Hopkins University, where he played varsity football, and earned his law degree with honors from New York Law School.

Kevin Manara departed from the Board of Governors in 2021, and is now considered part of the Emeritus Board of Governors.



Chris McCleary
*United States
Olympic &
Paralympic
Committee*

Chris McCleary joined the United States Olympic & Paralympic Committee in 2015 and serves as its General Counsel & Chief Operating Officer. In this role, he leads the USOPC teams in legal, compliance, ethics, NGB oversight, finance, information technology, events & logistics, and facilities. He also leads USOPC's governance work and serves as corporate secretary to the USOPC board of directors. McCleary oversees the USOPC's partnerships with the World Anti-doping Agency, U.S. Anti-doping Agency and Partnership for Clean Competition. He also serves as a member of the Association of National Olympic Committee's Legal Commission.



Ed Merrens
*M.D.
United States
Anti-Doping Agency*

Dr. Ed Merrens is Chief Clinical Officer for Dartmouth Health and Associate Professor of Medicine at the Geisel School of Medicine at Dartmouth. Dr. Merrens oversees clinical operations across the Dartmouth Health system. He is a Board Member of the U.S. Anti-Doping Agency (USADA). He has a long-standing involvement in international sports, serving as the team physician and medical director for the USA Biathlon from 1998-2014. He has served as team physician with the U.S. Olympic & Paralympic Committee for the World University Games in Beijing, China (2001) and Olympic Winter Games in Salt Lake City, United States (2002), Torino, Italy (2006), Vancouver, Canada (2010), and Sochi, Russia (2014). Dr. Merrens is a 1988 graduate of Dartmouth College, a 1994 graduate of the Geisel School of Medicine at Dartmouth and holds a 2013 Masters degree in Health Care Delivery Science from the Tuck School of Business and Dartmouth College. He works clinically as a Hospitalist at Dartmouth-Hitchcock Medical Center in Lebanon, NH.

STAFF & OFFICERS



Ryan Murphy
Executive Director


Ryan Murphy was named Executive Director for the Partnership for Clean Competition Research Collaborative in November 2021. In this role, Murphy oversees organizational strategy and daily operations – including budgeting, fundraising, business development, grant administration, scientific outreach, and communication with the PCC Board of Governors and Scientific Advisory Board. Murphy completed an MA in International Sports Law from Anglia Ruskin University in Chelmsford, England, as well as an MSc in Sport and Recreation Management from The University of Sheffield in Sheffield, England. He is a graduate of West Chester University of Pennsylvania with a BSc in Kinesiology. Murphy previously worked as an International Doping Control Officer for International Doping Tests & Management, from 2003 – 2015, conducting doping control tests (in-competition and out-of-competition) on athletes throughout the world.



David Kumbroch
Director of Communications

David Kumbroch started as the Director of Communications for the Partnership for Clean Competition in February 2020. In the role, he helps set the communications priorities and strategies for generating new grant applications, engaging stakeholders, and bringing in funders. He comes to Colorado Springs by way of Huntsville, Alabama, where he previously served as the Science Communications Specialist for the HudsonAlpha Institute for Biotechnology—a genetics research institute. His passion for communicating science started during his seven years as a journalist. Kumbroch graduated from the University of Alabama with a degree focused on broadcast journalism.

David Kumbroch was with the PCC throughout 2021, the year this report represents. He departed in 2022, replaced by Jocelyn Quiles.



Eric Kerzner
National Football League

PCC Treasurer

Eric Kerzner works for the National Football League as Vice President, Labor Relations, supporting Club football and finance executives with the financial components of player contracts and the salary cap. Eric's primary responsibilities include negotiating, administering, and enforcing the League's Collective Bargaining Agreements with the NFL Players Association on financial-related labor matters, including player contracts, the salary cap, compliance, and strategic planning. Eric is also a member of the bargaining team that negotiates with the NFL Referees Association. Prior to joining the NFL, Eric worked in public accounting at McGladrey and Pullen, LLP. Eric graduated from the University of Connecticut in 1996, with a Bachelor of Science degree in Accounting.



Lindsey Ingraham
Major League Baseball

PCC Secretary

Lindsey Ingraham serves as the Director of MLB Drug, Health and Safety Programs, where she assists in the administration of all of Major League Baseball's drug prevention and treatment programs, including program updates, testing, results management, and disciplinary measures. She works closely with the labs and collectors to manage all aspects of the testing and results reporting processes. Additionally, in this role, Lindsey plays a key part in the development and delivery of various educational initiatives. Every year she delivers educational programming to Minor League players during Spring Training, to newly drafted players upon signing, and to Top Prospects during the Arizona Fall League. Lindsey was hired by the Office of the Commissioner of Baseball as Specialist, MLB Drug, Health and Safety Programs in January 2015. Lindsey graduated from Cornell University in 2005 and The George Washington University Law School in 2010.

SCIENTIFIC ADVISORY BOARD Co-Chairs



James Dalton *Ph.D*

James T. Dalton, Ph.D. is Executive Vice President and Provost at the University of Alabama. He received his Bachelor of Science in Pharmacy from the University of Cincinnati (1986) and Doctor of Philosophy in pharmaceuticals and pharmaceutical chemistry from Ohio State University (1990). Dr. Dalton rose through the faculty ranks in the Department of Pharmaceutical


Sciences in the College of Pharmacy at the University of Tennessee (1992-2000) before returning to Ohio State where he served as Professor and Chair in the Division of Pharmaceutics (2000-2007). He began an entrepreneurial leave of absence from Ohio State in 2005 and finally left OSU in 2007 to devote his full time effort as Chief Scientific Officer at GTx, Inc. in Memphis, TN (2007-2014) where he oversaw the preclinical and clinical development of selective androgen receptor modulators and then served as Dean at the University of Michigan College of Pharmacy from 2014-2020. Dr. Dalton is co-inventor of enobosarm (aka ostarine; the first reported selective androgen receptor modulator) and is an elected member of the National Academy of Medicine.

Matthew Fedoruk *Ph.D*


Matthew Fedoruk, Ph.D. currently works as the Chief Science Officer at the U.S. Anti-Doping Agency (USADA). With more than 14 years of experience in antidoping and a Ph.D. in Pathology and Laboratory Medicine, Dr. Fedoruk also serves as a standing member of the IWF Anti-Doping Committee, the WADA Health, Medicine and Research Committee (HMRC), the TDSSA

Expert Group Chair and Athlete Biological Passport (ABP) Ad-Hoc Working Group.

Before joining USADA, Dr. Fedoruk worked at the Canadian Centre for Ethics in Sport (CCES) and served with the Vancouver 2010 Organizing Committee for the 2010 Olympic and Paralympic Winter Games in Canada. He currently lives in sunny Colorado Springs, Colorado, which is also known as 'Olympic Town USA' for being home to the U.S. Olympic Committee, the high-altitude Olympic Training Center, numerous national sport federations and USADA.



SCIENTIFIC ADVISORY BOARD



Gerhard Baumann
M.D.

Past Chief of Endocrinology and Metabolism at the Veterans Administration Lakeside Medical Center and the Associate Director of the Northwestern University General Clinical Research Center in Chicago, Dr. Baumann is a Professor of Medicine Emeritus at Northwestern University. Dr. Baumann characterized the complex nature of growth hormone in human blood, including its various isoforms. He discovered the growth hormone binding protein, the circulating ectodomain of the growth hormone receptor. He is also the co-discoverer of the first reported mutation in the growth hormone releasing hormone (GHRH) receptor gene causing a severe form of familial growth hormone deficiency. He has broad expertise in endocrinology, with particular emphasis on pituitary disease. He is an elected member of the American Society of Clinical Investigation and the Association of American Physicians.



Lori Bestervelt
Ph.D.

Dr. Lori Bestervelt is an Entrepreneurial Executive who brings the strong combination of technical and scientific expertise and business acumen, as well as deep P&L experience in product line expansion. She is proud of her high level of name recognition within the dietary supplements, U.S. professional sports nutrition and anti-doping industries. Lori completed Competition & Strategy through the Harvard Business School Executive Education and Corporate Innovation through MIT's Sloan Executive Education. She earned a Doctorate of Toxicology, a Master of Science in Nutritional Biochemistry and a Bachelor of Science in Microbiology & Immunology, all at the University of Michigan. She has been a Member of the Council for Responsible Nutrition and the American Herbal Products Association.



Larry Bowers
Ph.D.

As USADA'S Chief Science Officer from 2000 to 2016, Dr. Bowers provided leadership and scientific support for USADA's research sample collection planning, results management, arbitration, education programs, and the prestigious USADA Annual Symposium. Past Associate Editor (Drug Testing and Toxicology) for the journal, *Clinical Chemistry*, Dr. Bowers was the deputy director of the Athletic Drug Testing Laboratory for the 1996 Olympic Games, and has served on several scientific organizations Board of Directors.



Steve Elliot
Ph.D.

Steve retired from his Scientific Executive Director Position at Amgen in 2012, where he had worked since 1983. During his early years at the company, he performed structure-function studies on erythropoietin and the erythropoietin receptor and is the inventor of Aranesp, a re-engineered analog of rHuEpo with a longer serum half-life. He also played a key role when three cross country skiers who doped with Aranesp were caught and stripped of their gold medals and suspended from competition for two years following the 2002 Olympic Winter Games. Dr. Elliott continues to work in conjunction with the anti-doping movement.

SCIENTIFIC ADVISORY BOARD



Gary Green
M.D.

Gary Green, MD, was appointed Medical Director for Major League Baseball in 2010. He also serves as research director for MLB. He is a fellow in the American College of Physicians and American College of Sports Medicine and a Clinical Professor in the UCLA School of Medicine in the Division of Sports Medicine. Dr. Green is the head team physician for Pepperdine University and serves on the California Interscholastic Federation Medical Advisory Committee. He is also on review boards for USADA for adverse analytical findings and therapeutic use exemptions. He is in private practice in Pacific Palisades, California at the Medical Doctors of St. John's.



John Lombardo
M.D.

Dr. John Lombardo serves as the Independent Administrator for the NFL Policy on Performance-Enhancing Substances. He also served as a member of the WADA Therapeutic Use Exemption Expert Group, a reviewer of therapeutic use exemptions for USADA and PGA and a member of the Board of Directors for Sports Medicine Research and Testing Laboratory. He earned a bachelor's degree from the University of Dayton, his medical degree from The Ohio State University and completed his Family Medicine residency at St. Elizabeth's Medical Center in Dayton, Ohio. He served as Medical Director of the Section of Sports Medicine at the Cleveland Clinic and the Medical Director of Sports Medicine at Ohio State University.



Tom Martin
Ph.D.

Dr. Tom Martin is the Independent Program Administrator for Major League Baseball's Joint Drug Prevention and Testing Program. A native of Forked River, New Jersey, Dr. Martin received his ROTC commission into the Army Medical Service Corps in 1990 and entered Active Service after obtaining a Ph.D. in Inorganic Chemistry from Clemson University in 1995. As part of his military service, Dr. Martin directed two military drug testing laboratories. He culminated his Army career as the Director, Drug Testing and Program Policy in the Office of the Under Secretary of Defense for Personnel and Readiness. He retired from the Army in 2018 as a Colonel and started his current position with the MLB/MLB Players Association.



Alvin Matsumoto
M.D.

Dr. Matsumoto is a Professor Emeritus in the Division of Gerontology & Geriatric Medicine, Department of Medicine at the University of Washington (UW) School of Medicine, and Clinical Investigator in the Geriatric Research, Education and Clinical Center (GRECC) at the Veteran Affairs Puget Sound Health Care System (VAPSHCS) in Seattle. He serves as a member of the Board of Directors of the United States Anti-Doping Agency (USADA); President of the Board of Directors of the Seattle Institute for Biomedical and Clinical Research; and co-chair of the Partnership for the Accurate Testing of Hormones. Previously, he was Director of the Clinical Research Unit, Associate Director of the GRECC, Chief of Gerontology, and an Attending Physician at the VAPSHCS, and on the faculty at the UW for more than 40 years. His research expertise is in androgens and male reproductive endocrinology.


SCIENTIFIC ADVISORY BOARD



Annette Salmeen

D.Phil


Dr. Salmeen, D.Phil., was a 1996 Olympian and gold medalist. She served as an athlete's representative for the USA Swimming national governing body from 1996 to 2005. In 2005, she was elected as an athlete member of the U.S. Anti-Doping Agency Board of Directors and served until 2012. She was a member of the USADA board research committee and was also involved with efforts to support athlete education and the USADA True Sport initiative. She earned her doctoral degree in Biochemistry as a Rhodes Scholar at Oxford in 2001 and studied growth factor signaling pathways as a post-doctoral fellow in the Chemical and Systems Biology department at Stanford. She is currently a lecturer in the Human Biology Program at Stanford.



Michael Sawka

Ph.D

Chief Scientific Officer of Environmental Physiology and Hydration Associates, Adjunct Professor of Biological Sciences at Georgia Institute of Technology, past Department of Army Science and Technology Senior Scientist appointee, and Chief of Thermal and Mountain Medicine Division at the US Army Research Institute of Environmental Medicine. Dr. Sawka is an expert in environmental physiology (heat, cold, high-altitude), blood volume control, fluid/ electrolyte balance, temperature regulation, and exercise physiology. Dr. Sawka is a Fellow of the American Physiological Society and the American College of Sports Medicine.



Lawrence Silverman

Ph.D

Emeritus Professor of Pathology at the University of Virginia, Dr. Silverman also served as Director of the Molecular Diagnostics, Clinical Genomics, and Immunology Laboratories at the University of Virginia, as well as Director of the Division of Molecular Pathology, and Director of the Immunochemistry/Molecular Genetics Laboratory at the University of North Carolina Hospitals. Dr. Silverman is a diplomate of the American Board of Clinical Chemistry and a Fellow of the American College of Medical Genetics.

Lawrence Silverman departed from the Scientific Advisory Board in 2021, and is now considered part of the Emeritus Scientific Advisory Board.



John Yates III

Ph.D

The Ernest W. Hahn Professor in the Department of Chemical Physiology and Molecular & Cellular Neurobiology at The Scripps Research Institute, Dr. Yates is the lead inventor of the SEQUEST software for correlating tandem mass spectrometry data to sequences in the database and developer of the shotgun proteomics technique for analysis of protein mixtures. Dr. Yates was ranked by Citation Impact, Science Watch as one of the Top 100 Chemists for the decade, 2000-2010. Dr. Yates is the Editor in Chief at the Journal of Proteome Research.



2021 IN REVIEW



IN 2021



THE PCC FOCUSED ON
CONTINUED RESEARCH
FUNDING AND OPERATIONS,
DESPITE THE CONTINUED
PRESSURES OF COVID-19.

TO THAT END, IN 2021 THE PCC

HELD THE ORGANIZATION'S
FIRST VIRTUAL POSTER
SESSION TO SHARE
RESEARCH AND FACILITATE
DISCUSSION AMONG PEERS

58 POSTERS FROM 18
COUNTRIES

24 PODCAST EPISODES
8,665 DOWNLOADS/
LISTENS

24 GUESTS REPRESENTING
10 DIFFERENT COUNTRIES

LAUNCHED A NEW
APPLICATION SOLUTION TO
CENTRALIZE APPLYING &
REPORTING ON ONE EASY-
TO-USE PLATFORM

FACILITATED 52
PUBLICATIONS AND
PRESENTATIONS FROM
OUR FUNDED RESEARCH

BROUGHT TOGETHER 500+
COLLEAGUES FOR A WEBINAR SERIES
ON ANTI-DOPING IN THE
OLYMPIC/PARALYMPIC MOVEMENT

\$2,575,373
in Total Awards

APPROVED
GRANTS

THE PCC SELECTED
NEW PROJECTS
FROM **10** DIFFERENT
COUNTRIES

GRANTS

- **JAMES HOPKER**, UNIVERSITY OF KENT. *PERFORMANCE MONITORING FOR ANTI-DOPING.*
- **ANDY HOOFNAGLE**, UNIVERSITY OF WASHINGTON. *TRANSLATING SPECIFIC ASSAYS OF COLLAGEN TURNOVER.*
- **GEOFF MILLER**, SMRTL. *BIOTIN AS A MASKING AGENT FOR HCG USE - A FOLLOW-UP ADMINISTRATION STUDY.*
- **GEOFF MILLER**, SMRTL. *DETECTING THE ABUSE OF PELLET-DELIVERED TESTOSTERONE.*
- **MARIO THEVIS**, COLOGNE. *INVESTIGATIONS INTO THE METABOLISM AND THE DETECTION OF THE NOVEL SARM S42.*
- **BRADLEY JOHNSON**, TEXAS TECH UNIVERSITY. *RESIDUE ANALYSIS OF PROHIBITED ANABOLIC AGENTS IN THE MEAT SUPPLY CHAIN.*
- **JOHN EILER**, CALIFORNIA INSTITUTE OF TECHNOLOGY. *MOLECULAR ISOTOPICT STRUCTURE AS A TOOL FOR DOPING FORENSICS.*
- **NIKOS NTOUMANIS**, UNIVERSITY OF SOUTHERN DENMARK. *A META-ANALYSIS OF PSYCHOSOCIAL PREDICTORS OF DOPING INTENTIONS AND USE.*

MICRO-GRANTS

- **ANDY HOOFNAGLE**, UNIVERSITY OF WASHINGTON. *VALIDATION OF A NOVEL ASSAY FOR TYPE III COLLAGEN TURNOVER.*
- **DAVID COWAN**, KINGS COLLEGE LONDON. *IMPROVING THE DETECTION OF INSULINS BY USE OF THEIR DEGRADATION PRODUCTS.*
- **HOLLY COX**, SMRTL. *DETECTION OF INSULIN ANALOGUES IN URINE.*
- **GUENTER GMEINER**, SEIBERSDORF LABOR GMBH DOPING CONTROL LABORATORY. *SYNTHESIS AND CHARACTERIZATION OF REFERENCE MATERIALS FOR DOPING ANALYSIS: OSTARINE GLUCURONIDE: TRENBOLONE/EPTRINBOLONE GLUCURONIDES: METENOLONE GLUCURONIDE.*
- **OSCAR J POZO**, IMIM. *SCREENING OF GROWTH HORMONE ABUSE THROUGH THE ELEVATION OF TARGETED LIPIDIC COMPOUNDS (GHAELIC).*
- **DAVID HANDELSMAN**, ANZAC RESEARCH INSTITUTE. *PREVALENCE OF THYROID HORMONE ABUSE IN ELITE AUSTRALIAN ATHLETES.*
- **NICOLAS LEUENBERGER**, SWISS ANTI-DOPING LABORATORY. *HAEMOGLOBIN DETERMINATION IN DRIED BLOOD.*
- **MARIO THEVIS**, COLOGNE. *ORGAN-ON-A-CHIP: AN OPTION TO MIMIC THE HUMAN (LONG-TERM) METABOLISM?*
- **MARIO THEVIS**, COLOGNE. *CARBON ISOTOP RATIOS OF ENDOGENOUS STEROIDS FOUND IN A STEROID - METHOD DEVELOPMENT, VALIDATION AND REFERENCE POPULATION-DERIVED THRESHOLDS.*
- **MARIO THEVIS**, COLOGNE. *PROBING FOR THE PRESENCE OF SEMENOGELIN IN HUMAN URINE.*
- **GABE NAGY**, UNIVERSITY OF UTAH. *RAPID ANALYSIS OF ¹³C/¹²C ISOTOPOLOGUES FOR IMPROVED DETECTION OF STEROID ABUSE USING HIGH-RESOLUTION CYCLIC ION MOBILITY SEPARATIONS COUPLED TO MASS.*
- **DR. NASSER AL ANSARI**, ANTI-DOPING LABORATORY QATAR. *THE VALUE OF DRONES IN ANTI-DOPING.*

PUBLICATIONS

BELINSKAIA DA, SAVELIEVA EI, KARAKASHEV GV, ET AL. **INVESTIGATION OF BEMETHYLBOTRANSFORMATION PATHWAYS BY COMBINATION OF LC-MS/HRMS AND IN SILICOMETHODS.** INT J MOL SCI. 2021;22(16):9021. PUBLISHED 2021 AUG 21. DOI:10.3390/IJMS22169021 HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34445727/

COWAN DA, MONCRIEFFE DA. **PROCOLLAGEN TYPE III AMINO-TERMINAL PROPEPTIDE AND INSULIN-LIKE GROWTH FACTOR I AS BIOMARKERS OF GROWTH HORMONE ADMINISTRATION** [PUBLISHED ONLINE AHEAD OF PRINT, 2021 AUG 21]. DRUG TEST ANAL. 2021;10.1002/DTA.3155. DOI:10.1002/DTA.3155 HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34418311/

GARZINSKY AM, THOMAS A, KRUG O, THEVIS M. **PROBING FOR THE PRESENCE OF DOPING AGENTS IN EXHALED BREATH USING CHROMATOGRAPHIC/MASS SPECTROMETRIC APPROACHES RAPID COMMUN MASS SPECTROM.** 2021 JAN 15;35(1):E8939. DOI: 10.1002/RCM.8939. HTTPS://PUBMED.NCBI.NLM.NIH.GOV/32881194/

GÖRGENS C, RAMME AP, GUDDAT S, SCHRADER Y, WINTER A, DEHNE EM, HORLAND R, THEVIS M. **ORGAN-ON-A-CHIP: DETERMINE FEASIBILITY OF A HUMAN LIVER MICROPHYSIOLOGICAL MODEL TO ASSESS LONG-TERM STEROID METABOLITES IN SPORTS DRUG TESTING.** DRUG TEST ANAL. 2021 NOV;13(11-12):1921-1928. DOI: 10.1002/DTA.3161. EPUB 2021 SEP 22. HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34505743/

GÖSCHL L, GMEINER G, GÄRTNER P, STADLER G, ENEV V, THEVIS M, SCHÄNZER W, GUDDAT S, FORSDAHL G. **STANZOLOL-N-GLUCURONIDE METABOLITES IN HUMAN URINE SAMPLES AS SUITABLE TARGETS IN TERMS OF ROUTINE ANTI-DOPING ANALYSIS.** DRUG TEST ANAL. 2021 SEP;13(9):1668-1677. DOI: 10.1002/DTA.3109. EPUB 2021 JUN 9. HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34089570/

HAND,R.A., PILETSKA, E.,BASSINDALE, T., TURNER,N.W. & MORGANG. **APPLICATION OF COMPREHENSIVE2D CHROMATOGRAPHY IN THE ANTI-DOPING FIELD: SAMPLE IDENTIFICATION AND QUANTIFICATION.** J. CHROM B. IN PRESS DOI.ORG/10.1016/J.JCHROMB.2021.122584

HAND, R.A., WOLFF, K., BASSINDALE, T., TURNER, N.W. & MORGAN G. **RAPID SCREENING FOR ANABOLIC ANDROGENIC STEROIDS AND THEIR METABOLITES BY COMPREHENSIVE GCXGC-TOFMS.** J. CHROM.

HAND, R.A.,WOLFF, K., BASSINDALE,T., TURNER, N.W.& MORGAN G. **IDENTIFICATION ANDQUANTIFICATION OF ANABOLIC ANDROGENICSTERIODS AND THEIRMETABOLITES USING LOWENERGY ELECTRON IONISATIONAND TANDEM IONISATION GC-TOFMS.** ANALYTICAL CHEMISTRY.

KOWALCZYK K, TORRES-ELGUERA JC, JAREK A, KONOPKA A, KWIATKOWSKA D, BULSKA E. **IN VITRO METABOLIC STUDIES OF NOVEL SELECTIVE ANDROGENRECEPTOR MODULATORS AND THEIR USE FOR DOPING CONTROL ANALYSIS** [PUBLISHED ONLINE AHEAD OF PRINT, 2021 AUG 19]. DRUG TEST ANAL. 2021;10.1002/DTA.3151. DOI:10.1002/DTA.3151 HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34414676/

KNOOP A, FUSSHÖLLERG, HAENELT N, ET AL. **MASS SPECTROMETRIC CHARACTERIZATION OF URINARYHYDRAFINIL METABOLITES FOR ROUTINE DOPINGCONTROL PURPOSES** [PUBLISHED ONLINE AHEAD OF PRINT, 2021 AUG 10]. DRUG TEST ANAL. 2021;10.1002/DTA.3137. DOI:10.1002/DTA.3137 HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34378339/

LACOMBE, S.; JONES, A.; BRENNNA, J.T.; TOBIAS, H.J. **CRYOFOCUS FAST GC-IRMS FEATURING LOW TEMPERATURE CATALYTIC COMBUSTION REACTORS REDUCES ANALYTICAL RUNTIME FOR ANABOLIC STEROID TESTING.**

LACOMBE, S.; JONES, A.; BRENNNA, J.T.; TOBIAS, H.J. **LOW TEMPERATURE CATALYTIC COMBUSTION REACTOR INTEGRATED IN A CRYOFOCUS FAST GAS CHROMATOGRAPHY COMBUSTION ISOTOPE RATIO MASS SPECTROMETRY SYSTEM FOR THE RAPID ANALYSIS OF STEROIDS.**

LEE JH, YANG YJ, MIN AY, ET AL. **SCREENING AND ELUCIDATION OF FRAGMENTATIONS OF 23 DIURETICS IN DIETARY SUPPLEMENTS USING UHPLC-Q-ORBITRAP.** SCI JUSTICE. 2021;61(5):451-458. DOI:10.1016/J.SCIJUS.2021.05.004 HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34482925/

PUBLICATIONS

LOKE S, DE LA TORRE X, IANNONE M, ET AL. **CONTROLLED ADMINISTRATION OF DEHYDROCHLOROMETHYLTESTOSTERONE IN HUMANS: URINARY EXCRETION AND LONG-TERM DETECTION OF METABOLITES FOR ANTI-DOPING PURPOSE** [PUBLISHED ONLINE AHEAD OF PRINT, 2021 AUG 18]. J STEROID BIOCHEM MOL BIOL. 2021;105978. DOI:10.1016/J.JSBMB.2021.105978 [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34418529/](https://pubmed.ncbi.nlm.nih.gov/34418529/)

LORIA F, COX HD, VOSS SC, ROCCA A, MILLER GD, TOWNSEND N, GEORGAKOPOULOS C, EICHNER D, KUURANNE T, LEUENBERGER N. **THE USE OF RNA-BASED 5'-AMINOLEVULINATE SYNTHASE 2 BIOMARKERS IN DRIED BLOOD SPOTS TO DETECT RECOMBINANT HUMAN ERYTHROPOIETIN MICRODOSES.** DRUG TEST ANAL. 2022 MAY;14(5):826-832. DOI: 10.1002/DTA.3123. EPUB 2021 JUL 7. [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34216436/](https://pubmed.ncbi.nlm.nih.gov/34216436/)

MARCHAND A, ROY D, MONSHEIMER SA, LEWIS J, ERICSSON M. **DEVELOPMENT OF A MICROPLATE DUPLEX IMMUNOASSAY TO SIMPLIFY DETECTION OF GROWTH HORMONE DOPING: PROOF OF CONCEPT.** DRUG TEST ANAL. 2022 APR;14(4):724-732. DOI: 10.1002/DTA.3197. EPUB 2021 NOV 21. [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34761559/](https://pubmed.ncbi.nlm.nih.gov/34761559/)

MARTIN L, ERICSSON M, MARCHAND A. **MULTIPLEXED DETECTION OF AGENTS AFFECTING ERYTHROPOIESIS (AAES) AND OVERALL STRATEGY FOR OPTIMIZING INITIAL TESTING PROCEDURE** [PUBLISHED ONLINE AHEAD OF PRINT, 2021 AUG 2]. DRUG TEST ANAL. 2021;10.1002/DTA.3136. DOI:10.1002/DTA.3136 [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34342157/](https://pubmed.ncbi.nlm.nih.gov/34342157/)

MARTIN L, KAFI R, ZHOU X, ZHANG L, ERICSSON M, MARCHAND A. **DETECTION OF RECOMBINANT ERYTHROPOIETIN BIOSIMILAR JIMAIXIN™ AFTER ADMINISTRATION IN HEALTHY SUBJECTS** [PUBLISHED ONLINE AHEAD OF PRINT, 2021 AUG 14]. DRUG TEST ANAL. 2021;10.1002/DTA.3143. DOI:10.1002/DTA.3143 [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34391213/](https://pubmed.ncbi.nlm.nih.gov/34391213/)

NAIR VS, SHARPE K, HUSK J, MILLER GD, VAN EENOO P, CROUCH A, EICHNER D. **EVALUATION OF BLOOD PARAMETERS BY LINEAR DISCRIMINANT MODELS FOR THE DETECTION OF TESTOSTERONE ADMINISTRATION.** DRUG TEST ANAL. 2021 JUL;13(7):1270-1281. DOI: 10.1002/DTA.3017. EPUB 2021 MAR 11. [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/33629499/](https://pubmed.ncbi.nlm.nih.gov/33629499/)

POKRYWKAA, SKRZYPIEC-SPRING M, KRZYWAŃSKI J, RYNKOWSKI M, SAUGY M, FAISS R. **CASES REPORTS: UNINTENDED ANTI-DOPING RULE VIOLATION AFTER DORZOLAMIDE USE SEVERAL MONTHS PRIOR TO A DOPING CONTROL** [PUBLISHED ONLINE AHEAD OF PRINT, 2021 AUG 30]. DRUG TEST ANAL. 2021;10.1002/DTA.3156. DOI:10.1002/DTA.3156 [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34463045/](https://pubmed.ncbi.nlm.nih.gov/34463045/)

REICHEL C, ERCEG D, LORENC B, SCHEIBLHOFER V, FARMER L, ZANITZER K, GEISENDORFER T, GMEINER G, THEVIS M. **DATA FROM A MICRODOSED RECOMBINANT HUMAN ERYTHROPOIETIN ADMINISTRATION STUDY APPLYING THE NEW BIOTINYLATED CLONE AE7A5 ANTIBODY AND A FURTHER OPTIMIZED SARCOSYL POLYACRYLAMIDE GEL ELECTROPHORESIS PROTOCOL** DRUG TEST ANAL. 2021 JAN 15. DOI: 10.1002/DTA.2989. ONLINE AHEAD OF PRINT. [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/33450134/](https://pubmed.ncbi.nlm.nih.gov/33450134/)

REIHLEN P, BLOBEL M, WEISS P, HARTH J, WITTMANN J, LEENDERS F, THEVIS M. **INTRODUCTION OF A PEGYLATED EPO CONJUGATE AS INTERNAL STANDARD FOR EPO ANALYSIS IN DOPING CONTROLS,** DRUG TEST ANAL. 2021 DEC 14. DOI: 10.1002/DTA.3211. [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34905300/](https://pubmed.ncbi.nlm.nih.gov/34905300/)

ROCCA A, MARTIN L, KUURANNE T, ERICSSON M, MARCHAND A, LEUENBERGER N. **A FAST SCREENING METHOD FOR THE DETECTION OF CERA IN DRIED BLOOD SPOTS** [PUBLISHED ONLINE AHEAD OF PRINT, 2021 AUG 11]. DRUG TEST ANAL. 2021;10.1002/DTA.3142. DOI:10.1002/DTA.3142 [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34380180/](https://pubmed.ncbi.nlm.nih.gov/34380180/)

RUBIO A, GÖRGENS C, KRUG O, ET AL. **CHROMATOGRAPHIC-MASS SPECTROMETRIC ANALYSIS OF THE URINARY METABOLITE PROFILE OF CHLORPHENESIN OBSERVED AFTER DERMAL APPLICATION OF CHLORPHENESIN-CONTAINING SUNSCREEN** [PUBLISHED ONLINE AHEAD OF PRINT, 2021 AUG 25]. RAPID COMMUN MASS SPECTROM. 2021;E9183. DOI:10.1002/RCM.9183 [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34431558/](https://pubmed.ncbi.nlm.nih.gov/34431558/)

PUBLICATIONS

SOBOLEVSKY T, AHRENS B. **BIOTIN AS A MASKING AGENT IN CHORIONIC GONADOTROPIN ASSAYS UTILIZING BIOTINYLATED ANTIBODIES** [PUBLISHED ONLINE AHEAD OF PRINT, 2021 AUG 10]. DRUG TEST ANAL. 2021;10.1002/DTA.3141. DOI:10.1002/DTA.3141 [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34378342/](https://pubmed.ncbi.nlm.nih.gov/34378342/)

SOLHEIM SA, RINGSTED TK, NORDSBORG NB, DEHNES Y, LEVERNAES MCS, MØRKEBERG J. **NO PAIN, JUST GAIN: PAINLESS, EASY, AND FAST DRIED BLOOD SPOT COLLECTION FROM FINGERTIP AND UPPER ARM IN DOPING CONTROL** [PUBLISHED ONLINE AHEAD OF PRINT, 2021 AUG 3]. DRUG TEST ANAL. 2021;10.1002/DTA.3135. DOI:10.1002/DTA.3135 [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34346172/](https://pubmed.ncbi.nlm.nih.gov/34346172/)

SOLHEIM SA, LEVERNAES MCS, MØRKEBERG J, JUUL A, UPNERS EN, NORDSBORG NB, DEHNES Y. **STABILITY AND DETECTABILITY OF TESTOSTERONE ESTERS IN DRIED BLOOD SPOTS AFTER INTRAMUSCULAR INJECTIONS**. DRUG TEST ANAL. 2021 MAR 17. DOI: 10.1002/DTA.3030. ONLINE AHEAD OF PRINT. [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/33733610/](https://pubmed.ncbi.nlm.nih.gov/33733610/)

SUGASAWA T, NAKANO T, FUJITA SI, ET AL. **PROOF OF GENE DOPING IN A MOUSE MODEL WITH A HUMAN ERYTHROPOIETIN GENE TRANSFERRED USING AN ADENOVIRAL VECTOR**. GENES (BASEL). 2021;12(8):1249. PUBLISHED 2021 AUG 16. DOI:10.3390/GENES12081249 [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34440425/](https://pubmed.ncbi.nlm.nih.gov/34440425/)

THEVIS M. **BROADENING THE HORIZON OF ANTIDOPING ANALYTICAL APPROACHES USING DRIED BLOOD SPOTS**. CLIN CHEM. 2021 AUG 5;67(8):1041-1043. DOI: 10.1093/CLINCHEM/HVAB074. [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34060612/](https://pubmed.ncbi.nlm.nih.gov/34060612/)

THEVIS M, PIPERT, THOMAS A. **RECENT ADVANCES IN IDENTIFYING AND UTILIZING METABOLITES OF SELECTED DOPING AGENTS IN HUMAN SPORTS DRUG TESTING** [PUBLISHED ONLINE AHEAD OF PRINT, 2021 AUG 8]. J PHARM BIOMED ANAL. 2021;205:114312. DOI:10.1016/J.JPBA.2021.114312 [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34391136/](https://pubmed.ncbi.nlm.nih.gov/34391136/)

VOSS SC, YASSIN M, GRIVEL JC, ET AL. **RED BLOOD CELL DERIVED EXTRACELLULAR VESICLES DURING THE PROCESS OF AUTOLOGOUS BLOOD DOPING** [PUBLISHED ONLINE AHEAD OF PRINT, 2021 AUG 28]. DRUG TEST ANAL. 2021;10.1002/DTA.3157. DOI:10.1002/DTA.3157 [HTTPS://PUBMED.NCBI.NLM.NIH.GOV/34453778/](https://pubmed.ncbi.nlm.nih.gov/34453778/)

The image is a composite. On the left, there is a close-up of two laboratory test tubes in a blue rack. The tubes are graduated with markings from 5 to 15 mL. The tube in the foreground is partially filled with a light blue liquid, reaching the 12 mL mark. The background is a light blue gradient with faint, stylized molecular diagrams consisting of circles connected by lines. Overlaid on the right side of the image is the word "FINANCIALS" in a bold, blue, sans-serif font. A thick, dark blue horizontal bar is positioned directly beneath the text.

FINANCIALS

PARTNERSHIP FOR **clean competition**

**INDEPENDENT AUDITOR'S REPORT AND FINANCIAL STATEMENTS
DECEMBER 31, 2021**

The following documents are excerpts from an independent audit of the
Partnership for Clean Competition's finances.

Independent Auditor's Report

Board of Governors
Partnership for Clean Competition
Research Collaborative
Colorado Springs, Colorado

Opinion

We have audited the financial statements of Partnership for Clean Competition Research Collaborative (the Organization), which comprise the statements of financial position as of December 31, 2021 and 2020, and the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Organization as of December 31, 2021 and 2020, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern within one year after the date that these financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

BKD, LLP

Colorado Springs, Colorado
May 25, 2022

**Partnership for Clean Competition
Research Collaborative**
Statements of Financial Position
December 31, 2021 and 2020

Assets

	2021	2020
Cash and cash equivalents	\$ 1,739,816	\$ 2,057,868
Restricted cash	958,044	1,113,044
Contributions receivable	-	232,942
Prepaid expenses	5,470	24,359
Prepaid fellowship	28,125	91,156
	<hr/>	<hr/>
Total assets	<u><u>\$ 2,731,455</u></u>	<u><u>\$ 3,519,369</u></u>

Liabilities and Net Assets

Liabilities

Accounts payable and accrued liabilities	<u>\$ 633,028</u>	<u>\$ 87,146</u>
	<hr/>	<hr/>
Total liabilities	<u>633,028</u>	<u>87,146</u>

Net Assets

Without donor restrictions	2,098,427	3,407,223
With donor restrictions	<u>-</u>	<u>25,000</u>
	<hr/>	<hr/>
Total net assets	<u>2,098,427</u>	<u>3,432,223</u>
	<hr/>	<hr/>
Total liabilities and net assets	<u><u>\$ 2,731,455</u></u>	<u><u>\$ 3,519,369</u></u>

Partnership for Clean Competition Research Collaborative

Statements of Activities

Years Ended December 31, 2021 and 2020

	2021		2020	
	Without Donor Restrictions	With Donor Restrictions	Without Donor Restrictions	With Donor Restrictions
Revenues, Gains and Other Support				
Contributions	\$ 1,500,000	\$ -	\$ 1,750,000	\$ -
Write-off of uncollectible pledges	(74,609)	(25,000)	-	-
Other income	1,528	-	19,581	-
Net assets released from restrictions	-	-	295,198	(295,198)
Total revenues, gains and other support	1,426,919	(25,000)	2,064,779	(295,198)
Expenses and Losses				
Anti-doping research	2,544,354	-	4,501,155	-
Management and general	168,296	-	213,791	-
Fundraising	23,065	-	33,847	-
Total expenses and losses	2,735,715	-	4,748,793	-
Change in Net Assets	(1,308,796)	(25,000)	(2,684,014)	(295,198)
Net Assets, Beginning of Year	3,407,223	25,000	6,091,237	320,198
Net Assets, End of Year	\$ 2,098,427	\$ -	\$ 3,407,223	\$ 25,000

**Partnership for Clean Competition
Research Collaborative
Statement of Functional Expenses
Year Ended December 31, 2021**

	2021				
	Program Services	Support Services			
	Anti-Doping Research	Management and General	Fundraising	Total Support Services	Total
Research	\$ 2,112,640	\$ -	\$ -	\$ -	\$ 2,112,640
Fellowships and consultants	175,531	-	-	-	175,531
Salaries	121,640	34,754	17,377	52,131	173,771
Benefits	-	51,189	5,688	56,877	56,877
Travel	2,673	-	-	-	2,673
Supplies and office expenses	-	5,153	-	5,153	5,153
Website expenses	22,184	-	-	-	22,184
Insurance	-	19,749	-	19,749	19,749
Advertising	26,260	-	-	-	26,260
Intellectual property	77,042	-	-	-	77,042
Professional services and dues	6,384	57,451	-	57,451	63,835
	<u>\$ 2,544,354</u>	<u>\$ 168,296</u>	<u>\$ 23,065</u>	<u>\$ 191,361</u>	<u>\$ 2,735,715</u>
Total	<u>\$ 2,544,354</u>	<u>\$ 168,296</u>	<u>\$ 23,065</u>	<u>\$ 191,361</u>	<u>\$ 2,735,715</u>

**Partnership for Clean Competition
Research Collaborative
Statement of Functional Expenses
Year Ended December 31, 2020**

	2020				
	Program Services	Support Services			
	Anti-Doping Research	Management and General	Fundraising	Total Support Services	Total
Research	\$ 3,897,824	\$ -	\$ -	\$ -	\$ 3,897,824
Fellowships and consultants	342,211	-	-	-	342,211
Salaries	181,909	51,974	25,987	77,961	259,870
Benefits	-	67,058	7,451	74,509	74,509
Travel	7,274	-	-	-	7,274
Supplies and office expenses	-	6,025	-	6,025	6,025
Amortization	13,215	-	409	409	13,624
Website expenses	13,233	-	-	-	13,233
Insurance	-	18,207	-	18,207	18,207
Advertising	22,830	-	-	-	22,830
Intellectual property	13,971	-	-	-	13,971
Professional services and dues	8,688	70,527	-	70,527	79,215
Total	\$ 4,501,155	\$ 213,791	\$ 33,847	\$ 247,638	\$ 4,748,793

**Partnership for Clean Competition
Research Collaborative**
Statements of Cash Flows
Years Ended December 31, 2021 and 2020

	2021	2020
Operating Activities		
Change in net assets	\$ (1,333,796)	\$ (2,979,212)
Items not requiring (providing) cash		
Amortization	-	13,624
Changes in		
Contributions receivable	232,942	1,217,058
Prepaid expenses	18,889	(7,793)
Prepaid fellowship	63,031	35,944
Accounts payable and accrued liabilities	545,882	17,225
	<u>(473,052)</u>	<u>(1,703,154)</u>
Net cash used in operating activities	<u>(473,052)</u>	<u>(1,703,154)</u>
Change in Cash, Cash Equivalents and Restricted Cash	(473,052)	(1,703,154)
Cash, Cash Equivalents and Restricted Cash, Beginning of Year	<u>3,170,912</u>	<u>4,874,066</u>
Cash, Cash Equivalents and Restricted Cash, End of Year	<u><u>\$ 2,697,860</u></u>	<u><u>\$ 3,170,912</u></u>
Reconciliation of Cash, Cash Equivalents and Restricted Cash on the Statements of Financial Position		
Cash and cash equivalents	\$ 1,739,816	\$ 2,057,868
Restricted cash	<u>958,044</u>	<u>1,113,044</u>
Total cash, cash equivalents and restricted cash	<u><u>\$ 2,697,860</u></u>	<u><u>\$ 3,170,912</u></u>